Published • loading... • Updated
Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
Summary by Pharma Excipients
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
August, 2026 Commercialization follows strong interest from pharmaceutical developers worldwide Ashland Inc. (NYSE: ASH), has announced the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines. The launch comes …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
